AKT1 and cancer: A study conducted in 2019 revealed that the combination of RSV with bicalutamide or an antagonist of CXCR4 (a chemokine receptor known to be upregulated in several cancers) inhibited the AKT signaling pathway, which resulted in the inhibition of prostate cancer progression [126].